vs

Side-by-side financial comparison of IRONWOOD PHARMACEUTICALS INC (IRWD) and NCS Multistage Holdings, Inc. (NCSM). Click either name above to swap in a different company.

NCS Multistage Holdings, Inc. is the larger business by last-quarter revenue ($50.6M vs $47.7M, roughly 1.1× IRONWOOD PHARMACEUTICALS INC). NCS Multistage Holdings, Inc. runs the higher net margin — 29.5% vs -4.8%, a 34.3% gap on every dollar of revenue. On growth, NCS Multistage Holdings, Inc. posted the faster year-over-year revenue change (12.5% vs -47.3%). IRONWOOD PHARMACEUTICALS INC produced more free cash flow last quarter ($74.6M vs $12.9M). Over the past eight quarters, NCS Multistage Holdings, Inc.'s revenue compounded faster (7.4% CAGR vs -20.2%).

Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.

NCS Multistage Holdings, Inc. is a global oilfield services and energy technology provider specializing in engineered completion systems for onshore and offshore oil and gas production. It offers multistage fracturing tools that optimize well performance, serving major operators across North America, Latin America, the Middle East and Asia-Pacific, focusing on boosting operational efficiency and resource recovery for upstream energy clients.

IRWD vs NCSM — Head-to-Head

Bigger by revenue
NCSM
NCSM
1.1× larger
NCSM
$50.6M
$47.7M
IRWD
Growing faster (revenue YoY)
NCSM
NCSM
+59.8% gap
NCSM
12.5%
-47.3%
IRWD
Higher net margin
NCSM
NCSM
34.3% more per $
NCSM
29.5%
-4.8%
IRWD
More free cash flow
IRWD
IRWD
$61.7M more FCF
IRWD
$74.6M
$12.9M
NCSM
Faster 2-yr revenue CAGR
NCSM
NCSM
Annualised
NCSM
7.4%
-20.2%
IRWD

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IRWD
IRWD
NCSM
NCSM
Revenue
$47.7M
$50.6M
Net Profit
$-2.3M
$15.0M
Gross Margin
Operating Margin
14.3%
10.3%
Net Margin
-4.8%
29.5%
Revenue YoY
-47.3%
12.5%
Net Profit YoY
-200.9%
331.0%
EPS (diluted)
$0.01
$5.43

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IRWD
IRWD
NCSM
NCSM
Q4 25
$47.7M
$50.6M
Q3 25
$122.1M
$46.5M
Q2 25
$85.2M
$36.5M
Q1 25
$41.1M
$50.0M
Q4 24
$90.5M
$45.0M
Q3 24
$91.6M
$44.0M
Q2 24
$94.4M
$29.7M
Q1 24
$74.9M
$43.9M
Net Profit
IRWD
IRWD
NCSM
NCSM
Q4 25
$-2.3M
$15.0M
Q3 25
$40.1M
$3.8M
Q2 25
$23.6M
$924.0K
Q1 25
$-37.4M
$4.1M
Q4 24
$2.3M
$3.5M
Q3 24
$3.6M
$4.1M
Q2 24
$-860.0K
$-3.1M
Q1 24
$-4.2M
$2.1M
Operating Margin
IRWD
IRWD
NCSM
NCSM
Q4 25
14.3%
10.3%
Q3 25
61.8%
6.6%
Q2 25
53.2%
-5.6%
Q1 25
-70.7%
8.6%
Q4 24
34.8%
6.5%
Q3 24
28.0%
6.9%
Q2 24
26.5%
-14.0%
Q1 24
14.7%
5.7%
Net Margin
IRWD
IRWD
NCSM
NCSM
Q4 25
-4.8%
29.5%
Q3 25
32.8%
8.2%
Q2 25
27.7%
2.5%
Q1 25
-90.9%
8.1%
Q4 24
2.5%
7.7%
Q3 24
4.0%
9.4%
Q2 24
-0.9%
-10.4%
Q1 24
-5.6%
4.7%
EPS (diluted)
IRWD
IRWD
NCSM
NCSM
Q4 25
$0.01
$5.43
Q3 25
$0.23
$1.37
Q2 25
$0.14
$0.34
Q1 25
$-0.23
$1.51
Q4 24
$0.03
$1.34
Q3 24
$0.02
$1.60
Q2 24
$-0.01
$-1.21
Q1 24
$-0.03
$0.82

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IRWD
IRWD
NCSM
NCSM
Cash + ST InvestmentsLiquidity on hand
$215.5M
$36.7M
Total DebtLower is stronger
$5.3M
Stockholders' EquityBook value
$-261.8M
$126.2M
Total Assets
$396.9M
$181.2M
Debt / EquityLower = less leverage
0.04×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IRWD
IRWD
NCSM
NCSM
Q4 25
$215.5M
$36.7M
Q3 25
$140.4M
$25.3M
Q2 25
$92.9M
$25.4M
Q1 25
$108.5M
$23.0M
Q4 24
$88.6M
$25.9M
Q3 24
$88.2M
$15.3M
Q2 24
$105.5M
$18.6M
Q1 24
$121.5M
$14.0M
Total Debt
IRWD
IRWD
NCSM
NCSM
Q4 25
$5.3M
Q3 25
$199.5M
$5.1M
Q2 25
$199.3M
$5.5M
Q1 25
$199.2M
$5.4M
Q4 24
$199.0M
$6.0M
Q3 24
$198.8M
$6.5M
Q2 24
$198.6M
$6.8M
Q1 24
$398.3M
$6.4M
Stockholders' Equity
IRWD
IRWD
NCSM
NCSM
Q4 25
$-261.8M
$126.2M
Q3 25
$-264.2M
$110.1M
Q2 25
$-308.2M
$106.4M
Q1 25
$-334.1M
$103.2M
Q4 24
$-301.3M
$98.8M
Q3 24
$-311.3M
$96.0M
Q2 24
$-321.7M
$91.0M
Q1 24
$-330.5M
$93.7M
Total Assets
IRWD
IRWD
NCSM
NCSM
Q4 25
$396.9M
$181.2M
Q3 25
$396.1M
$162.0M
Q2 25
$342.9M
$158.0M
Q1 25
$327.2M
$155.1M
Q4 24
$350.9M
$152.8M
Q3 24
$389.5M
$145.8M
Q2 24
$395.6M
$139.4M
Q1 24
$438.8M
$140.9M
Debt / Equity
IRWD
IRWD
NCSM
NCSM
Q4 25
0.04×
Q3 25
0.05×
Q2 25
0.05×
Q1 25
0.05×
Q4 24
0.06×
Q3 24
0.07×
Q2 24
0.08×
Q1 24
0.07×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IRWD
IRWD
NCSM
NCSM
Operating Cash FlowLast quarter
$74.6M
$13.1M
Free Cash FlowOCF − Capex
$74.6M
$12.9M
FCF MarginFCF / Revenue
156.3%
25.5%
Capex IntensityCapex / Revenue
0.0%
0.4%
Cash ConversionOCF / Net Profit
0.88×
TTM Free Cash FlowTrailing 4 quarters
$127.0M
$21.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IRWD
IRWD
NCSM
NCSM
Q4 25
$74.6M
$13.1M
Q3 25
$47.6M
$7.2M
Q2 25
$-15.1M
$3.5M
Q1 25
$20.0M
$-1.6M
Q4 24
$15.2M
$10.6M
Q3 24
$9.9M
$-2.0M
Q2 24
$33.5M
$6.0M
Q1 24
$45.0M
$-1.9M
Free Cash Flow
IRWD
IRWD
NCSM
NCSM
Q4 25
$74.6M
$12.9M
Q3 25
$47.6M
$6.9M
Q2 25
$-15.1M
$3.2M
Q1 25
$19.9M
$-2.1M
Q4 24
$10.4M
Q3 24
$9.9M
$-2.5M
Q2 24
$33.4M
$5.6M
Q1 24
$44.9M
$-2.2M
FCF Margin
IRWD
IRWD
NCSM
NCSM
Q4 25
156.3%
25.5%
Q3 25
39.0%
14.9%
Q2 25
-17.7%
8.9%
Q1 25
48.4%
-4.2%
Q4 24
23.1%
Q3 24
10.8%
-5.6%
Q2 24
35.4%
19.0%
Q1 24
60.0%
-5.0%
Capex Intensity
IRWD
IRWD
NCSM
NCSM
Q4 25
0.0%
0.4%
Q3 25
0.0%
0.5%
Q2 25
0.0%
0.8%
Q1 25
0.1%
0.9%
Q4 24
0.0%
0.5%
Q3 24
0.0%
1.0%
Q2 24
0.1%
1.1%
Q1 24
0.1%
0.7%
Cash Conversion
IRWD
IRWD
NCSM
NCSM
Q4 25
0.88×
Q3 25
1.19×
1.88×
Q2 25
-0.64×
3.81×
Q1 25
-0.41×
Q4 24
6.74×
3.07×
Q3 24
2.71×
-0.49×
Q2 24
Q1 24
-0.91×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IRWD
IRWD

Segment breakdown not available.

NCSM
NCSM

Products$33.8M67%
Services$16.8M33%

Related Comparisons